Infinity Pharma rises after promising data from cancer therapy study

Infinity Pharmaceuticals

10/12/2021 14:23

** Shares of drug developer  INFI.O  up ~7% at $2.49
premarket, its highest in nearly a month
    ** Co reports positive updated data from ongoing mid-stage
study of drug candidate - eganelisib, in combination with other
cancer drugs, Tecentriq and Abraxane, in treating a type of
aggressive breast cancer  urn:newsml:reuters.com:*:nBw8Kl51pa 
    ** Study showed tumor reduction in 92.8% of patients with
PD-L1 positive tumors and 85.2% of patients with PD-L1 negative
tumors, both being types of cancerous tumors 
    ** Study also showed disease control rate or percentage of
patients with complete or partial reduction in cancer post
treatment to be 92.8% in patients with PD-L1 positive tumors and
81.4% in patients with PD-L1 negative tumors
    ** Study did not show any new safety signals and its safety
profile was consistent with expectations for three component
drugs
    ** Co presented this data at 2021 San Antonio Breast Cancer
Symposium
    ** Up to Thursday's close, stock had risen 9.43% YTD 
    
    

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))